

# Dan Jones

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11286431/publications.pdf>

Version: 2024-02-01

136  
papers

11,932  
citations

22153

59  
h-index

26613

107  
g-index

137  
all docs

137  
docs citations

137  
times ranked

9581  
citing authors

#	ARTICLE	IF	CITATIONS
1	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 161-168.	1.4	24
2	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	5.2	34
3	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	1.4	127
4	Molecular and Cytogenetic Education in Hematopathology Fellowship. <i>American Journal of Clinical Pathology</i> , 2019, 152, 438-445.	0.7	3
5	Resistance mechanism for ibrutinib in marginal zone lymphoma. <i>Blood Advances</i> , 2019, 3, 500-502.	5.2	17
6	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3049-3049.	1.4	2
7	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1008-1011.	1.3	29
8	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. <i>Gynecologic Oncology</i> , 2017, 146, 588-595.	1.4	77
9	Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines. <i>Leukemia Research</i> , 2017, 60, 129-134.	0.8	3
10	Virtual Airway Skills Trainer (VAST) Simulator. <i>Studies in Health Technology and Informatics</i> , 2016, 220, 91-7.	0.3	12
11	The oncogenic <i>JUNB</i> / <i>CD</i> 30 axis contributes to cell cycle deregulation in <i>ALK</i> + anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 514-523.	2.5	25
12	T-Cell Receptor Signaling in Peripheral T-Cell Lymphoma – A Review of Patterns of Alterations in a Central Growth Regulatory Pathway. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 163-172.	2.3	27
13	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. <i>Blood</i> , 2011, 117, 3641-3647.	1.4	71
14	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. <i>Cancer</i> , 2011, 117, 572-580.	4.1	46
15	Prognostic value of <i>FLT3</i> mutations among different cytogenetic subgroups in acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 2145-2155.	4.1	91
16	Practical advice for determining the role of <i>BCR-ABL</i> mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 1800-1811.	4.1	72
17	Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. <i>Blood</i> , 2010, 115, 5428-5429.	1.4	10
18	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. <i>Blood</i> , 2010, 116, 2070-2077.	1.4	319

#	ARTICLE	IF	CITATIONS
19	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. <i>Cancer</i> , 2010, 116, 3631-3637.	4.1	29
20	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. <i>Cancer Science</i> , 2010, 101, 2005-2010.	3.9	13
21	Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome. <i>Histopathology</i> , 2010, 57, 785-795.	2.9	32
22	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. <i>Journal of Clinical Oncology</i> , 2010, 28, 392-397.	1.6	231
23	Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 398-404.	1.6	227
24	A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2010, 23, 1524-1534.	5.5	12
25	Flow cytometric detection of peripheral blood involvement by mycosis fungoides and S�azary syndrome using T-cell receptor V�2 chain antibodies and its application in blood staging. <i>Modern Pathology</i> , 2010, 23, 284-295.	5.5	58
26	Approaches to Classification of Lymphoma and Leukemia. , 2010, , 3-20.		1
27	Molecular Diagnostics and Cytogenetic Testing. , 2010, , 61-95.		0
28	Classification of T-cell and NK-cell Malignancies. , 2010, , 391-412.		0
29	Cutaneous T-cell Lymphomas. , 2010, , 427-447.		3
30	Histiocytic and Dendritic Cell Neoplasms. , 2010, , 459-475.		0
31	Designing Targeted Therapies for Lymphomas and Leukemias. , 2010, , 611-626.		0
32	Functional Classification of Peripheral T-Cell Lymphomas as an Approach to Improve Outcome Prediction and Therapy Selection. <i>Seminars in Hematology</i> , 2010, 47, S1-S4.	3.4	3
33	Histiocytic and Dendritic Cell Neoplasms. <i>Surgical Pathology Clinics</i> , 2010, 3, 1165-1183.	1.7	11
34	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1478-1484.	1.3	4
35	Chronic Myelogenous Leukemia. <i>Molecular Pathology Library</i> , 2010, , 387-394.	0.1	0
36	Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms. <i>Journal of Clinical Oncology</i> , 2009, 27, 5425-5430.	1.6	67

#	ARTICLE	IF	CITATIONS
37	Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance. <i>Journal of Clinical Oncology</i> , 2009, 27, 3642-3649.	1.6	94
38	Effective Treatment of Acute Promyelocytic Leukemia With All- <i>trans</i> -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. <i>Journal of Clinical Oncology</i> , 2009, 27, 504-510.	1.6	355
39	Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 4-11.	2.8	72
40	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. <i>Blood</i> , 2009, 113, 2154-2160.	1.4	151
41	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. <i>Blood</i> , 2009, 113, 6315-6321.	1.4	153
42	High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 4675-4686.	1.4	88
43	The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas. <i>Cancer</i> , 2008, 112, 552-561.	4.1	19
44	Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. <i>Cancer</i> , 2008, 113, 985-994.	4.1	120
45	Utility of CD26 in flow cytometric immunophenotyping of T-cell lymphomas in tissue and body fluid specimens. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 341-348.	1.5	18
46	CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 480-484.	1.2	47
47	Reply to the Letter to the Editor from Oudejans et al. <i>Clinical Cancer Research</i> , 2008, 14, 2515-2515.	7.0	1
48	High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. <i>Blood</i> , 2008, 111, 328-337.	1.4	120
49	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. <i>Blood</i> , 2008, 111, 1774-1780.	1.4	140
50	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. <i>Blood</i> , 2008, 112, 53-55.	1.4	127
51	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. <i>Blood</i> , 2008, 112, 5190-5192.	1.4	36
52	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , 2008, 112, 4839-4842.	1.4	75
53	Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP). <i>Blood</i> , 2008, 112, 182-182.	1.4	24
54	Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). <i>Blood</i> , 2008, 112, 446-446.	1.4	9

#	ARTICLE	IF	CITATIONS
55	Rooting into the Soil, a Model for the Role of Sox4 in Leukemia. <i>Blood</i> , 2008, 112, 3794-3794.	1.4	1
56	CD4+/CD56+ Hematodermic Tumor. <i>American Journal of Clinical Pathology</i> , 2007, 127, 687-700.	0.7	158
57	Philadelphia Chromosome-Positive Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2007, 127, 642-650.	0.7	163
58	TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10175-10180.	7.1	22
59	Cutaneous T-Cell and NK-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2007, 127, 670-686.	0.7	34
60	Distribution Patterns of Dendritic Cells and T Cells in Diffuse Large B-Cell Lymphomas Correlate with Prognoses. <i>Clinical Cancer Research</i> , 2007, 13, 6666-6672.	7.0	52
61	MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. <i>Blood</i> , 2007, 109, 500-502.	1.4	363
62	Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. <i>Blood</i> , 2007, 109, 497-499.	1.4	150
63	Oral-Cutaneous CD4-Positive T-cell Lymphoma: A Study of Two Patients. <i>American Journal of Dermatopathology</i> , 2007, 29, 62-67.	0.6	14
64	TCL1 in B-cell Tumors Retains its Normal B-cell Pattern of Regulation and is a Marker of Differentiation Stage. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1123-1129.	3.7	28
65	c-Jun Expression and Activation are Restricted to CD30+ Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2007, 31, 447-453.	3.7	42
66	Skin involvement in T-cell prolymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 533-534.	1.2	14
67	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. <i>Blood</i> , 2007, 110, 4005-4011.	1.4	284
68	Identification and Validation of Biomarkers of IgVH Mutation Status in Chronic Lymphocytic Leukemia Using Microfluidics Quantitative Real-Time Polymerase Chain Reaction Technology. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 546-555.	2.8	23
69	Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2007, 136, 439-447.	2.5	137
70	Dynamics of BCR-ABL1 Transcripts during Dasatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).. <i>Blood</i> , 2007, 110, 2962-2962.	1.4	0
71	Dynamics of BCR-ABL1 Transcripts during Nilotinib Therapy in Patients with Chronic Myeloid Leukemia (CML).. <i>Blood</i> , 2007, 110, 2961-2961.	1.4	0
72	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i> , 2006, 107, 3469-3473.	1.4	371

#	ARTICLE	IF	CITATIONS
73	Eradication of minimal residual disease in hairy cell leukemia. <i>Blood</i> , 2006, 107, 4658-4662.	1.4	120
74	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , 2006, 108, 1421-1423.	1.4	85
75	Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. <i>Modern Pathology</i> , 2006, 19, 1555-1562.	5.5	84
76	Cytogenetic anomalies in hyaline vascular Castleman disease: report of two cases with reappraisal of histogenesis. <i>Cancer Genetics and Cytogenetics</i> , 2006, 164, 110-117.	1.0	27
77	Molecular approaches towards characterization, monitoring and targeting of viral-associated hematological malignancies. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 831-841.	3.1	5
78	Differential Expression of WT1 Gene Product in Non-Hodgkin Lymphomas. <i>Applied Immunohistochemistry &amp; Molecular Morphology</i> , 2005, 13, 132-137.	2.0	26
79	Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. <i>British Journal of Haematology</i> , 2005, 130, 726-728.	2.5	33
80	JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. <i>Modern Pathology</i> , 2005, 18, 1365-1370.	5.5	69
81	Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. <i>Modern Pathology</i> , 2005, 18, 1343-1349.	5.5	40
82	Mature T-cell leukemias. <i>Cancer</i> , 2005, 104, 1808-1818.	4.1	28
83	T-Cell Prolymphocytic Leukemia Involving Extramedullary Sites. <i>American Journal of Clinical Pathology</i> , 2005, 123, 456-464.	0.7	50
84	T Cell Leukemia-1 Modulates TCR Signal Strength and IFN- $\beta$ Levels through Phosphatidylinositol 3-Kinase and Protein Kinase C Pathway Activation. <i>Journal of Immunology</i> , 2005, 175, 864-873.	0.8	33
85	Peripheral T-Cell Lymphoma With a "Follicular" Pattern and the Perifollicular Sinus Phenotype. <i>American Journal of Clinical Pathology</i> , 2005, 123, 448-455.	0.7	16
86	Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2005, 11, 3425-3432.	7.0	256
87	Primary Sezary Syndrome Commonly Shows Low-Grade Cytologic Atypia and an Absence of Epidermotropism. <i>American Journal of Clinical Pathology</i> , 2005, 123, 510-515.	0.7	59
88	EBV-Associated B-and T-Cell Posttransplant Lymphoproliferative Disorders Following Primary EBV Infection in a Kidney Transplant Recipient. <i>American Journal of Clinical Pathology</i> , 2005, 123, 222-228.	0.7	34
89	Primary cutaneous B-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 478-483.	1.2	65
90	Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. <i>Human Pathology</i> , 2005, 36, 747-755.	2.0	51

#	ARTICLE	IF	CITATIONS
91	T-Cell Prolymphocytic Leukemia: A Single-Institution Experience. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 234-239.	1.4	31
92	Degree of CD25 Expression in T-Cell Lymphoma Is Dependent on Tissue Site. <i>Clinical Cancer Research</i> , 2004, 10, 5587-5594.	7.0	34
93	Distribution and Prognosis of WHO Lymphoma Subtypes in Taiwan Reveals a Low Incidence of Germinal-Center Derived Tumors. <i>Leukemia and Lymphoma</i> , 2004, 45, 1375-1384.	1.3	45
94	Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 4095-4102.	1.6	98
95	Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. <i>Modern Pathology</i> , 2004, 17, 954-961.	5.5	98
96	The Role of the Perifollicular Sinus in Determining the Complex Immunoarchitecture of Angioimmunoblastic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1632-1640.	3.7	12
97	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 489-495.	3.7	52
98	A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. <i>Blood</i> , 2004, 104, 328-335.	1.4	182
99	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome <sup>+</sup> positive chronic-phase chronic myeloid leukemia after failure of interferon- $\gamma$ . <i>Blood</i> , 2004, 104, 1979-1988.	1.4	163
100	The Current State and Future of Clonality Studies in Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2003, 121, ix-x.	0.7	13
101	Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease. <i>Human Pathology</i> , 2003, 34, 835-840.	2.0	102
102	Dissolution of the Lymphoid Follicle Is a Feature of the HHV8+ Variant of Plasma Cell Castleman's Disease. <i>American Journal of Surgical Pathology</i> , 2003, 27, 91-100.	3.7	54
103	TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. <i>Blood</i> , 2003, 101, 5007-5009.	1.4	182
104	Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. <i>Oncology Reports</i> , 2003, 10, 1513-8.	2.6	12
105	Apoptosis and Proliferation in Subcutaneous Panniculitis-Like T-Cell Lymphoma. <i>Modern Pathology</i> , 2002, 15, 625-631.	5.5	30
106	Peripheral T-Cell Lymphoma Arising in the Liver. <i>American Journal of Clinical Pathology</i> , 2002, 118, 574-581.	0.7	25
107	Apoptotic Rate in Peripheral T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2002, 118, 328-334.	0.7	58
108	CD4 <sup>-</sup> CD8 <sup>-</sup> 'Double-Negative' Cutaneous T-Cell Lymphomas Share Common Histologic Features and an Aggressive Clinical Course. <i>American Journal of Surgical Pathology</i> , 2002, 26, 225-231.	3.7	63



#	ARTICLE	IF	CITATIONS
109	Mantle Cell Lymphoma Involving Skin. American Journal of Surgical Pathology, 2002, 26, 1312-1318.	3.7	86
110	Radiotherapy Alone for Lymphocyte-Predominant Hodgkin's Disease. Cancer Journal (Sudbury, Mass ), 2002, 8, 377-383.	2.0	64
111	Cutaneous and Systemic Plasmacytosis in a Patient of Asian Descent Living in the United States. American Journal of Dermatopathology, 2002, 24, 241-245.	0.6	27
112	Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell Neoplasms. American Journal of Surgical Pathology, 2002, 26, 630-636.	3.7	91
113	Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood, 2002, 100, 3369-3373.	1.4	133
114	Dismantling the Germinal Center: Comparing the Processes of Transformation, Regression, and Fragmentation of the Lymphoid Follicle. Advances in Anatomic Pathology, 2002, 9, 129-138.	4.3	34
115	European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer, 2002, 94, 1731-1738.	4.1	67
116	CD56 <sup>+</sup> TdT <sup>+</sup> blastic natural killer cell tumor of the skin. Cancer, 2002, 94, 2401-2408.	4.1	128
117	Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. Journal of Cutaneous Pathology, 2002, 29, 465-472.	1.3	73
118	A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clinical Pathology, 2002, 2, 5.	1.8	58
119	CD56 TdT blastic natural killer cell tumor of the skin. Cancer, 2002, 94, 2401-2408.	4.1	5
120	Phenotypic Characterization of Subsets of T Cell Lymphoma: Towards a Functional Classification of T Cell Lymphoma. Leukemia and Lymphoma, 2001, 40, 449-459.	1.3	20
121	Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. International Journal of Dermatology, 2001, 40, 505-511.	1.0	27
122	The T-Cell Chemokine Receptor CXCR3 Is Expressed Highly in Low-Grade Mycosis Fungoides. American Journal of Clinical Pathology, 2001, 115, 413-421.	0.7	80
123	A Novel Four-Color PCR Assay to Assess T-Cell Receptor Gamma Gene Rearrangements in Lymphoproliferative Lesions. American Journal of Clinical Pathology, 2001, 116, 17-24.	0.7	83
124	Hepatosplenic gamma/delta T-Cell Lymphoma in Bone Marrow. American Journal of Clinical Pathology, 2001, 116, 410-419.	0.7	107
125	Absence of CD26 Expression Is a Useful Marker for Diagnosis of T-Cell Lymphoma in Peripheral Blood. American Journal of Clinical Pathology, 2001, 115, 885-892.	0.7	179
126	Expression of Stromal-Derived Factor-1 Is Decreased by IL-1 and TNF and in Dermal Wound Healing. Journal of Immunology, 2001, 166, 5749-5754.	0.8	126



#	ARTICLE	IF	CITATIONS
127	Reticulum Cell Sarcoma of Lymph Node with Mixed Dendritic and Fibroblastic Features. <i>Modern Pathology</i> , 2001, 14, 1059-1067.	5.5	51
128	A Chromosomal Abnormality in Hyaline Vascular Castleman's Disease. <i>American Journal of Surgical Pathology</i> , 2000, 24, 882-888.	3.7	82
129	Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. <i>Blood</i> , 2000, 96, 685-690.	1.4	138
130	The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2000, 95, 627-632.	1.4	178
131	Recurrences in Nodal T-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2000, 114, 438-447.	0.7	12
132	Precursor B-cell Lymphoblastic Lymphoma. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1480-1490.	3.7	203
133	The Chemokine Receptor CXCR4 Is Required for the Retention of B Lineage and Granulocytic Precursors within the Bone Marrow Microenvironment. <i>Immunity</i> , 1999, 10, 463-471.	14.3	635
134	Primary-Effusion Lymphoma and Kaposi's Sarcoma in a Cardiac-Transplant Recipient. <i>New England Journal of Medicine</i> , 1998, 339, 444-449.	27.0	169
135	Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 9448-9453.	7.1	1,537
136	Cytologic Diagnosis of Primary Serous Lymphoma. <i>American Journal of Clinical Pathology</i> , 1996, 106, 359-364.	0.7	18